Suven Life Sciences Limited (BOM:530239)

Market Cap	51.39B
Revenue (ttm)	75.74M
Net Income (ttm)	-1.43B
Shares Out	218.07M
EPS (ttm)	-6.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	67,288
Average Volume	142,763
Open	221.00
Previous Close	222.35
Day's Range	220.65 - 226.40
52-Week Range	96.00 - 256.60
Beta	0.82
RSI	59.37
Earnings Date	May 28, 2025

About Suven Life Sciences

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 recepto...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1989
• Employees: 141
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530239

Financial Performance

In 2023, Suven Life Sciences's revenue was 116.93 million, a decrease of -13.99% compared to the previous year's 135.95 million. Losses were -1.05 billion, -11.15% less than in 2022.